<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5428">
  <stage>Registered</stage>
  <submitdate>11/09/2005</submitdate>
  <approvaldate>11/09/2005</approvaldate>
  <nctid>NCT00180310</nctid>
  <trial_identification>
    <studytitle>SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System</studytitle>
    <scientifictitle>A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions</scientifictitle>
    <utrn />
    <trialacronym>SPIRIT II</trialacronym>
    <secondaryid>03-364</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Disease</healthcondition>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <healthcondition>Coronary Restenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - XIENCE V® Everolimus Eluting Coronary Stent
Treatment: devices - TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent

Experimental: 1 - XIENCE V® Everolimus Eluting Coronary Stent System

Active Comparator: 2 - TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent


Treatment: devices: XIENCE V® Everolimus Eluting Coronary Stent
Drug eluting stent implantation stent in the treatment of coronary artery disease.

Treatment: devices: TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent
Drug eluting stent implantation stent in the treatment of coronary artery disease

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>In-stent late loss (LL)</outcome>
      <timepoint>at 180 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>In-segment Late Loss</outcome>
      <timepoint>at 180 days (all patients) and at 2 years (for a subset of 152 patients)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-stent Late Loss at 2 years (for a subset of 152 patients)</outcome>
      <timepoint>at 2 years (for a subset of 152 patients)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proximal and distal Late Loss</outcome>
      <timepoint>at 180 days (all patients) and at 2 years (for a subset of 152 patients)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-stent and in-segment Angiographic Binary Restenosis (ABR) rate</outcome>
      <timepoint>at 180 days (all patients) and at 2 years (for a subset of 152 patients)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-stent and in-segment percent Diameter Stenosis (% DS)</outcome>
      <timepoint>at 180 days (all patients) and at 2 years (for a subset of 152 patients)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-stent percent Volume Obstruction (% VO)</outcome>
      <timepoint>at 180 days and at 2 years for a subset of 152 patients</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plaque behind the stent( by IVUS)</outcome>
      <timepoint>at 180 days and at 2 years for a subset of 152 patients</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia Driven Major Adverse Cardiac Event (ID-MACE) rate</outcome>
      <timepoint>at 30, 180 and 270 days, 1, 2, 3, 4 and 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia Driven Target Vessel Failure (ID-TVF)</outcome>
      <timepoint>at 30, 180 and 270 days, 1, 2, 3, 4 and 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ischemia Driven Target Lesion Revascularization (ID-TLR)</outcome>
      <timepoint>at 30, 180 and 270 days, 1, 2, 3, 4 and 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Persisting incomplete stent apposition, late-acquired incomplete stent apposition</outcome>
      <timepoint>at 180 days and at 2 years for a subset of 152 patients</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Aneurysm, thrombosis and persisting dissection</outcome>
      <timepoint>at 180 days (all patients) and at 2 years (for a subset of 152 patients)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Acute success(device, procedure and clinical)</outcome>
      <timepoint>Acute</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  De novo Target lesion(s) must be located in a native epicardial vessel with diameter
             between 2.25 mm and 4.25 mm by visual estimate

          -  The target lesion(s) must be in a major artery or branch with a visually estimated
             stenosis of &gt;= 50% and &lt; 100% with a TIMI flow of &gt;= 1

          -  Non-study, percutaneous intervention for lesions in a non-target vessel is allowed if
             done &gt;= 90 days prior to the index procedure or if planned to be done &gt; 9 months after
             the index procedure</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  De novo target lesion(s) located in a major epicardial vessel or a side branch that
             has been previously treated with any type of percutaneous intervention (e.g., balloon
             angioplasty, stent, cutting balloon, atherectomy) &lt; 9 months prior to index procedure

          -  Target lesion(s) restenotic from previous intervention

          -  Target lesion(s) located in a major epicardial vessel that has been previously treated
             with brachytherapy

          -  Target vessel(s) contains visible thrombus

          -  Patient has a high probability that a procedure other than pre-dilatation, stenting
             and post-dilatation will be required at the time of index procedure for treatment of
             the target vessel (e.g. atherectomy, cutting balloon or brachytherapy)

          -  Patient has additional clinically significant lesion(s) (&gt; 50% diameter stenosis) in a
             target vessel or side branch for which an intervention within 9 months after the index
             procedure may be required</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>300</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liège</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aalborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Oeynhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Segeberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dachau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kassel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>New Delhi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Breda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nieuwegein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zwolle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Epsom</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Abbott Vascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Prospective, randomized, active-control, single blind, parallel two-arm multi-center clinical
      trial comparing XIENCE V® Everolimus Eluting Coronary Stent System to the approved
      commercially available active control TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent
      System.

      TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent System is manufactured by Boston
      Scientific.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00180310</trialwebsite>
    <publication>Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, Sudhir K, Boland J, Huber K, Garcia E, te Riele JA; SPIRIT II Investigators. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2009 Dec;2(12):1190-8. doi: 10.1016/j.jcin.2009.10.002.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Patrick Serruys</name>
      <address>Erasmus Medical Center, Thoraxcenter, Rotterdam, the Netherlands</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>